PTHS Stock Analysis: Buy, Sell, or Hold?
PTHS - Pelthos Therapeutics Inc.
$29.50
0.22 (0.75%)
▲
5d:
+11.32%
30d:
+8.86%
90d:
+34.09%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When PTHS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PTHS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PTHS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PTHS is currently trading at $29.50, which is considered extended relative to its 30-day fair value range of $25.96 to $28.13.
Technical Outlook: Technically, PTHS is in a uptrend. The price is approaching resistance at $28.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PTHS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $57.71 (+95.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PTHS is in a uptrend. The price is approaching resistance at $28.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PTHS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $57.71 (+95.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$25.96 -
$28.13
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 95.6% below Wall St target ($57.71)
Trading Range Analysis
30-Day Trading Range
$25.96 -
$28.13
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$25.25
Resistance Level
$28.02
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.88
Wall Street Target
$57.71
(+95.6%)
Profit Margin
-186.2%
Share & Embed Analysis
Last updated: June 24, 2026 9:06 AM ET
Data refreshes hourly during market hours. Next update: 10:06 AM
Data refreshes hourly during market hours. Next update: 10:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTHS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ezra M Friedberg
SELL
558 shares
2026-04-02
Peter Greenleaf
SELL
797 shares
2026-04-02
Richard Malamut
SELL
590 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
